Protara Therapeutics, Inc.

NasdaqGM TARA

Protara Therapeutics, Inc. Free Cash Flow for the Trailing 12 Months (TTM) ending September 30, 2024: USD -35.26 M

Protara Therapeutics, Inc. Free Cash Flow is USD -35.26 M for the Trailing 12 Months (TTM) ending September 30, 2024, a -3.92% change year over year. Free cash flow is the amount of cash a company generates after accounting for cash outflows to support operations and maintain its capital assets.

Protara Therapeutics, Inc. Free Cash Flow for the Trailing 12 Months (TTM) ending September 30, 2023 was USD -33.93 M, a -19.08% change year over year.
Protara Therapeutics, Inc. Free Cash Flow for the Trailing 12 Months (TTM) ending September 30, 2022 was USD -28.50 M, a 19.56% change year over year.
Protara Therapeutics, Inc. Free Cash Flow for the Trailing 12 Months (TTM) ending September 30, 2021 was USD -35.42 M, a -24.68% change year over year.
Protara Therapeutics, Inc. Free Cash Flow for the Trailing 12 Months (TTM) ending September 30, 2020 was USD -28.41 M, a -433.04% change year over year.

Key data

Date	Free Cash Flow	Operating Cash Flow	Net Cash Used For Investing Activities	Net Cash Used Provided By Financing Activities

NasdaqGM: TARA

Protara Therapeutics, Inc.

CEO	Mr. Jesse Shefferman
IPO Date	Oct. 22, 2014
Location	United States
Headquarters	345 Park Avenue South
Employees	26
Sector	Health Care
Industries Biotechnology Clinical Trials Pharmaceuticals

Description

Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the identifying and advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy for the treatment of lymphatic malformations. It also develops intravenous choline chloride, an investigational phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease. The company was formerly known as ArTara Therapeutics, Inc. and changed its name to Protara Therapeutics, Inc. in May 2020. Protara Therapeutics, Inc. is headquartered in New York, New York.

Key trends

Past 5 years